Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy

The introduction of BCR–ABL tyrosine kinase inhibitors such as imatinib has changed the treatment of chronic myelogenous leukemia (CML). More than 75% of patients achieve complete cytogenetic remission (CCR) after treatment with imatinib, which provides an opportunity to collect minimally involved h...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Bashir, Qaiser, De Lima, Marcos J., McMannis, John D., Garcia-Manero, Guillermo, Shpall, Elizabeth, Kantarjian, Hagop, Cortes, Jorge E., O’Brien, Susan M., Jones, Dan, Qazilbash, Muzaffar, Wei, Wei, Giralt, Sergio A., Champlin, Richard E., Hosing, Chitra
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2010
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4188823/
https://ncbi.nlm.nih.gov/pubmed/20658954
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2010.501534
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg